Last checked at 21 Jan 2020 12:48
Avacta Group Hires Vectura Group CFO Fry As Non-Executive Director
Avacta Group Hires Vectura Group CFO Fry As Non-Executive Director
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Avacta Group Share News (AVCT)
AVCT Share
Price
AVCT Share
News
AVCT Share
Chat45
AVCT Share
Trades74
AVCT
Live RNS
AVCT Share
Charts
AVCT Level 2
Console
AVCT Live
Share Price
AVCT Broker
Ratings
AVCT Directors
Deals
AVCT Financial
Diary
AVCT
Fundamentals
AVCT Short
Positions1
AVCT
Media
Avacta Group Information
Share Price Information for Avacta Group (AVCT)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
45.50
Bid:
45.00
Ask:
46.00
Change:
-1.25 (-2.67%)
Spread:
1.00 (2.222%)
Open:
45.75
High:
46.25
Low:
45.50
Prev. Close:
46.75
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.8 Jan 2020 15:27
Avacta Group enters joint venture with South Korea's Daewoong
(Sharecast News) - Biotherapeutics and reagents developer Avacta Group has agreed to establish a joint venture in South Korea with Daewoong Pharmaceutical, it announced on Wednesday, and to enter into a collaboration and license agreement for the joint venture to develop the next generation of cell and gene therapies, incorporating its 'Affimer' proteins to enhance the immune-modulatory effects.
Read more8 Jan 2020 10:40
Avacta To Establish Gene Therapy Joint Venture With Daewoong Pharma
Avacta To Establish Gene Therapy Joint Venture With Daewoong Pharma
Read more13 Nov 2019 13:51
Avacta Expands Contract With LG Chem After First Programme Completes
Avacta Expands Contract With LG Chem After First Programme Completes
Read more13 Nov 2019 11:50
Avacta Group reports solid progress in partnership with LG Chem
(Sharecast News) - Biotherapeutics developer Avacta Group updated the market on the 'Affimer' therapeutics development partnership and license agreement with LG Chem Life Sciences, part of the South Korean LG Group, to develop Affimer therapeutics in several disease areas on Wednesday.
Read more4 Nov 2019 18:15
Avacta Non-Executive Sam Williams Steps Down After General Meeting
Avacta Non-Executive Sam Williams Steps Down After General Meeting
Read more18 Oct 2019 13:20
Avacta Plans GBP9 Million Fundraise; Loss Widens On Research Costs
Avacta Plans GBP9 Million Fundraise; Loss Widens On Research Costs
Read more10 Oct 2019 11:24
Avacta Teams With ADC Therapeutics To Develop Affimer-Drug Conjugates
Avacta Teams With ADC Therapeutics To Develop Affimer-Drug Conjugates
Read more10 Oct 2019 08:39
Avacta inks collaboration deal with ADC Therapeutics
(Sharecast News) - Biotechnology company Avacta Group has entered a collaboration and option agreement with ADC Therapeutics, which it described as a Switzerland-based clinical-stage oncology-focused biotechnology company pioneering the development of "highly potent and targeted" antibody-drug conjugates for patients suffering from haematological malignancies and solid tumours.
Read more20 Jun 2019 10:28
Avacta partners with Selexis ahead of first-in-human trials
(Sharecast News) - Avacta Group announced on Thursday that it has partnered with life sciences company Selexis to develop the Chinese hamster ovary (CHO) cell line, which will be used to manufacture Avacta's first 'Affimer' clinical candidate for first-time-in-human clinical trials.
Read more10 Jun 2019 10:51
Avacta Selects Candidate For First Human Trials Of Affimer Platform
LONDON (Alliance News) - Avacta Group PLC on Monday said it has selected a clinical development candidate AVA004 for first-time-in-human clinical trials of its Affimer platform.Affimer an a
Read more3 Jun 2019 10:20
Avacta To Submit Application For TMAC Linker Testing In Tumours Study
LONDON (Alliance News) - Avacta Group PLC on Monday said it is planning to submit an application to test its TMAC linker in patients with selected solid tumours in early 2020.The company, a
Read more9 Apr 2019 12:11
Avacta falls as stuttering revenues exacerbate losses
(Sharecast News) - Avacta Group's shares slid on Tuesday as interim revenues dropped on the back of a lower contribution from the life sciences division, which resulted in wider losses.
Read more9 Apr 2019 10:37
Avacta shares fall as interim revenues slide
(Sharecast News) - Biotherapeutics and research reagents developer Avacta Group reported a fall in half-year revenues to £1.0m on Tuesday, from £1.5m a year earlier.
Read more9 Apr 2019 09:49
Avacta Shares Fall On Widened Interim Loss, Lower Revenue
LONDON (Alliance News) - Avacta Group PLC on Tuesday reported a widened first half loss mainly due to lower income contribution from life sciences unit.The stock was trading 8.5% lower on a
Read more